羟基喜树碱为主治疗肝癌64例疗效观察

本文报告以羟基喜树碱为主治疗肝癌６４例。其中单独使用１９例，联合化疗４５例。按全国通用肝癌疗效评定标准，本组完全缓解１例，部分缓解７例，稳定９例，有效率２６．６％。中位生存期６个月。平均生存９．０３月，半年生存率为４６．９％，１年生存率为２６．６％。联合化疗组的疗效较单独使用组为优。在与ＭＭＣ、５－ＦＵ联合化疗的１２例中，平均生存１１．２７月，一年生存率及有效率均为４１．７％。表明羟基喜树碱治疗肝癌不仅疗效确切，而且与ＭＭＣ、５－ＦＵ组合在某些不能使用强烈化疗如ＦＡＭ、ＭＦＣ方案治疗的中晚期肝癌又提供了一条新的化疗方案。     

小剂量表阿霉素引起频发性室性早搏一例

小剂量表阿霉素引起频发性室性早搏一例山东省阳谷县医院李泽锋，王秀霞患者女，３３岁。心悸、胸闷１天，于１９９５年９月１７日入院。１年前患乳腺癌行根治术，术后用ＣＭＦ方案化疗３周期。１月前开始用ＣＡＦ方案（ＣＴＸ，表阿霉素，５－Ｆｕ）化疗２周期，共用表阿...     

高剂量动脉灌注化疗加药物滤过治疗局部晚期复发性直肠癌：初…

我院从１９８８年９月至１９９１年６月有７例局部晚期复发性直肠癌接受腹主动脉大剂量灌注化疗加药物滤过治疗。所用的药物是丝裂霉素Ｃ（ＭＭＣ，４０－５０ｍｇ）和５－氟尿嘧啶（５－ＦＵ，２０００ｍｇ）７例中，５例疼痛缓解，２例肿瘤缩小。４例治疗后６－１２个月死亡（平均生存１０．５月）；３例治疗后０．５－２０个月，仍存活。     

顺铂、氟尿嘧啶合用大剂量醛氢叶酸治疗晚期鼻咽癌

目的：对比观察大剂量醛氢叶酸（ＣＦ）、５－氟尿嘧啶（５－Ｆｕ）、顺铂（ＤＤＰ）（ＰＦＬ方案）与ＤＤＰ＋５－Ｆｕ（ＰＦ方案）联合化疗对晚期鼻咽癌的临床疗效及安全性。方法：１９９７年１月－１９９９年１月间,５８例经病理证实的晚期鼻咽癌患者,非随机分为ＰＦＬ组２８例（按ＰＦＬ方案化疗）,ＰＦ组３０例（按ＰＦ方案化疗）。结果：ＰＦＬ组ＣＲ率、有效率分别为１７．９％、６４．３％,中位生存期１４月（４－２１月     

泰素为主联合化疗治疗晚期乳腺癌及卵巢癌10例

我科于１９９７年９月至１９９８年５月,应用美国百时美施贵宝公司生产的泰素联合化疗,治疗１０例晚期癌患者,现将治疗结果报告如下。１材料与方法１．１临床资料１０例中乳腺癌６例,均行根治术以后行辅助性放化疗后复发和（或）转移的患者,其中有２例在复发转移后曾用过ＡＤＭ、ＣＢＰ、ＣＴＸ、５－ＦＵ联合化疗。卵巢癌４例行手术以后复发,其中３例用过ＰＤＤ、５－ＦＵ、ＶＰ－１６联合方案化疗２～３疗程,１例未用过化疗。１０例病例的年龄２７～６０岁,中位４８岁。１．２用药方法泰素联合ＣＦ或ＣＯＦ方案化疗,每次用量为Ｃ…     

腹腔大容积化疗预防大肠癌术后腹腔及肝转移的研究

目的：研究腹腔大容积化疗预防大肠癌术后腹腔复发及肝转移的效果。方法自１９９５年６月－１９９９年１２月将大肠癌术后患者分成２组：Ａ组５５例采用经埋藏式化疗泵行大容积腹腔化疗,Ｂ组４３例行常规静脉化疗（ＣＦ／５－Ｆｕ方案）,比较两者术后肝及腹腔复发的发生率、发生时间及术后存活时间。结果Ａ组５５例中,有２例于术后９、１５个空复发,２例于术后１３、１６个月出现肝转移,发生率为８．３％,５１例（９２．７％）     

低剂量粒—巨噬细胞集落刺激因子在肺癌化疗中的应用

３１例肺癌患者大剂量化疗４０例次，采用配对法分成加用低剂量粒－巨噬细胞集落刺激因子（ＧＭ－ＣＳＦ）的治疗组及不加用的对照组（二组均为２０例次）。结果表明，低剂量ＧＭ－ＣＳＦ明显缩短化疗所致白细胞低下的时间：治疗组为１４．５±９．４９天，对照组为１９．４±８．８５天（Ｐ＝０．０２），同时提高白细胞下降最低值：治疗组为３．３５×１０９／Ｌ±１．３７×１０９／Ｌ，对照组为２．９×１０９／Ｌ±１．１８×１０９／Ｌ。低剂量ＧＭ－ＣＳＦ的主要不良反应为发热（８０％）及肌痛、骨痛（１０％）。结果提示：低剂量ＧＭ－ＣＳＦ能支持癌症患者的大剂量化疗及连续化疗     

动脉灌注化疗药物及LAK／IL—2治疗晚期贲门癌

为观察经皮动脉灌注化疗药物及ＬＡＫ／ＩＬ－２治疗晚期贲门癌的疗效，采用经皮穿刺胃左动脉插管灌注健康人外周血ＬＡＫ细胞１×１０８／Ｌ及ＩＬ－２３０万Ｕ，化疗药物为表阿霉素３０ｍｇ、卡铂３００ｍｇ、长春地辛（西艾克）４ｍｇ或５－Ｆｕ１０００ｍｇ，每３周～４周一次，２次为一疗程，结果：经病理学确诊的共７８例晚期贲门癌患者经此法共介入灌注１４６次，最多者５次，最少者１次，胃部病灶ＣＲ＋ＰＲ占６１．５％，生存最长４１个月，最短４个月，中位生存期９．５个月，半年生存率为７６．９％，１年生存率为３０．８％，提示采用肿瘤供血动脉进行区域性灌注生物制剂及化疗药物，对于失去手术机会的晚期贲门癌病人不失为可供选择的有效治疗手段。     

5－Fu联合大剂量醛氢叶酸合并同步放疗中晚期直肠癌的临床研究

我院对１８例进展期直肠癌进行了氟脲嘧啶（５－Ｆｕ）联合大剂量醛氢叶酸（ＣＦ）化疗合并同步放疗的临床研究。ＣＦ２００ｍｇ／日，５－Ｆｕ３７５ｍｇ／ｍ２／日静脉滴注，每日一次连用５天为一疗程。放疗与化疗同步，体外照射全盆腔ＤＴ５０Ｇｙ／２５次／５周，直肠腔内高剂量率放疗Ｄ５－２０Ｇｙ／３－４次／２周。近期疗效完全缓解（ＣＲ）５例，部分缓解（ＰＲ）１０例，好转（ＭＲ）３例。有效率８３．３４％。中位效应持续时间１４个月。ＣＦ／５－Ｆｕ合并同步放疗是治疗进展期直肠癌的有效方法，近期反应及并发症尚在进一步观察中。     

G－CSF对小儿恶性血液病及肿瘤化疗后作用的动态观察

１０例小儿恶性肿瘤病人在接受强化疗后给予Ｇ－ＣＳＦ５－１０ｕｇ／ｋｇ／ｄ。９／１０例平均４天，１／１０例在１４天时白细胞总数上升至５．０×１０￣９／Ｌ以上，全部病例在停Ｇ－ＣＳＦ后４８～７２小时时出现第二次血象下跌。并观察到６／１０例在Ｇ－ＣＳＦ后平均第５天外周血出现幼稚细胞，３／７例骨髓粒系原始＋幼稚细胞不同程度升高，分别为２０％、２６％、８％，停用Ｇ－ＣＳＦ一周后未经任何化疗自然恢复正常，提示这些原始细胞来自正常的造血干细胞。     

CLINICAL-STUDY OF MULTIPLE-MYELOMA IN THE ELDERLY

From January 1989 until December 1992, 120 elderly patients over 65 years old with multiple myeloma (MM) were enrolled with the Elderly Hematology Study Group (EHSG) with 14 institutions participating. Several courses of chemotherapy were conducted in 103 of the 120 patients, 33 patients with alpha-interferon (IFN) and 70 patients without IFN. The response rate (CR+PR) was 24.0% of all 120 cases, 24.2% of the group treated with IFN and 25.7% of those treated without IFN. Similarly, the efficacy rate (CR+PR+MR) of these groups were 78.8%, 81.8% and 78.8%, respectively. The 50% survival time was 31 months in the 120 cases as a whole, 44 months in the group treated with IFN and 38 months in the group treated without IFN. No significant difference was observed either in response rate (p=0.243) or survival time (p=0.262) in the groups treated with or without IFN.     

顺氯氨铂、丝裂霉素和平阳霉素联合治疗食管癌41例结果

1986年7月～1987年12月采用顺氯氨铂、丝裂霉素、平阳霉素联合化疗治疗食管癌41例。完全缓解6例(14.6％),部分缓解17例(41.5％),微效9例(21.9％),稳定4例(9.8％),无效5例(12.2％)。完全缓解和部分缓解率(CR+PR)56.1％,总有效率(CR+PR+MR)78％,中位生存期7个月(2—32个月)。毒副反应有食欲减退,恶心、呕吐、脱发、发热、骨髓抑制.     

GP和FP治疗转移性鼻咽癌的疗效观察

目的：观察吉西他滨＋顺铂（GP）方案和氟尿嘧啶＋顺铂（FP）方案治疗晚期复发转移性鼻咽癌的疗效及不良反应。方法：选择放疗后复发转移性鼻咽癌60例,分别采用GP方案或FP方案静脉化疗,21天为1周期。结果：GP组：CR5例、PR19例,有效率（CR＋PR）80％;FP组：CR2例、PR14例,有效率（CR＋PR）53．3％两组有效率有显著差异（P=0．0283）。中位PFS（无进展生存期）GP组8个月,FP组3个月（P=0．0001）。中位OS期（总生存期）GP组11个月,FP组7个月（P=0．0002）。两组毒性均能耐受。结论：GP方案较FP可以更好改善复发转移性鼻咽癌的RR、PFS和OS。     

Treatment of postmenopausal breast cancer with bisbromoacetyl hexestrol

Twenty five cases of advanced postmenopausal breast cancer patients were treated with bisbromoacetyl hexestrol 3 CR and 5 PR were achieved. The response rate was 32%, and the average duration of remission 6 months. Vaginal bleeding was seen in 9 cases, 4 of whom were compelled to discontinue treatment.     

高渗溶液加大剂量BCNU治疗非手术肺癌多发脑转移14例

 本文报道了静脉用大剂量20%甘露醇(10me/kg)加大剂量BCNU(卡氮芥)(15mg/kg—45mg/kg)治疗非手术肺癌多发脑转移14例,收得了3例CR、5例PR、近斯缓解率(RR)57%(8/14)、中位生存期8个月的临床效果。     

The Therapy of Primary Adult Systemic CD30-Positive Anaplastic Large Cell Lymphoma: Results of 40 Cases Treated in a Single Center

The outcome of a series of adult patients, affected by primary systemic CD30-positive ana-plastic large cell lymphoma (ALCL), treated with a sequential intensive therapeutic program, has been analyzed and all data available in the literature have been reviewed. Forty consecutive, unselected patients with ALCL were treated with the F-MACHOP regimen, followed by radiotherapy (RT) for residual mediastinal disease (15 cases) and by autologous stem cell transplantation (ASCT) conditioned with BAVC (29 cases). Eighty-nine percent (32/36) of the patients younger than 60 years were eligible for completing the sequential treatment. Since then, 3 patients in CR refused ASCT, 1 was excluded for cardiac toxicity and 3 progressed and died of disease. Thus, 29 have been so far submitted to the transplant procedure. CR and PR rates were 40% and 45% respectively after CHT; 52.5% and 35% after RT; 80% and 5% after ASCT, with 78% of patients transplanted in PR convertin to a CR. Actuarial overall survival is 85% at 48.5 months (93% at 66 months for the 29 transplanted patients) and disease free survival is 100% at 54 and 64 months respectively, with no relapses observed among patients who reached a CR.

Considering our data and those of the literature, it can be concluded that although the role of ASCT in the therapy of ALCL must not be considered as definitive, its efficacy in converting PR into CR and in preventing relapses, suggests that a randomized trial comparing CHT alone vs CHT+ASCT should be undertaken.     

The therapy of primary adult systemic CD30-positive anaplastic large cell lymphoma: results of 40 cases treated in a single center.

The outcome of a series of adult patients, affected by primary systemic CD30-positive anaplastic large cell lymphoma (ALCL), treated with a sequential intensive therapeutic program, has been analyzed and all data available in the literature have been reviewed. Forty consecutive, unselected patients with ALCL were treated with the F-MACHOP regimen, followed by radiotherapy (RT) for residual mediastinal disease (15 cases) and by autologous stem cell transplantation (ASCT) conditioned with BAVC (29 cases). Eighty-nine percent (32/36) of the patients younger than 60 years were eligible for completing the sequential treatment. Since then, 3 patients in CR refused ASCT, 1 was excluded for cardiac toxicity and 3 progressed and died of disease. Thus, 29 have been so far submitted to the transplant procedure. CR and PR rates were 40% and 45% respectively after CHT; 52.5% and 35% after RT; 80% and 5% after ASCT, with 78% of patients transplanted in PR convertin to a CR. Actuarial overall survival is 85% at 48.5 months (93% at 66 months for the 29 transplanted patients) and disease free survival is 100% at 54 and 64 months respectively, with no relapses observed among patients who reached a CR. Considering our data and those of the literature, it can be concluded that although the role of ASCT in the therapy of ALCL must not be considered as definitive, its efficacy in converting PR into CR and in preventing relapses, suggests that a randomized trial comparing CHT alone vs CHT+ASCT should be undertaken.     

DCF方案治疗晚期胃癌患者的临床分析

目的:观察DCF方案治疗局部进展期或转移性胃癌的疗效和不良反应。方法:自2007年10月至2009年8月,42例晚期胃癌患者采用DCF,DXT(多西紫杉醇)75mg/m2,静脉滴注,第1天;DDP(顺铂)25 mg/m2,第1-3天;CF(亚叶酸钙)200mg/d,静脉滴注2小时,第1-5天;5-FU(氟尿嘧啶)500mg/m2,第1-5天,静脉滴注5-6小时,3周为1周期,方案治疗,按WHO标准评价近期疗效和不良反应,随访疾病进展时间(TTP)和中位生存期(MST)。结果:全组42例均可评价疗效,其中CR 3例,PR 19例,SD 11例,PD 9例。有效率(RR)为54.7%,中位TTP为5.5个月,中位MST为10个月。不良反应主要是骨髓抑制及胃肠道反应,其次为口腔黏膜炎、腹泻及周围神经毒性。结论:DCF方案治疗晚期胃癌的疗效较好,不良反应可以耐受。     

砷剂治疗急性早幼粒细胞白血病耐药的初步研究

目的　探讨Ａｓ２ Ｏ３ 对ＡＰＬ病人的获得性耐药或内在性耐药。方法　８６ 例用Ａｓ２ Ｏ３ 巩固治疗的ＡＰＬ病人在第１次ＣＲ后３ ａ内复发的２３例,２０ 例继续使用Ａｓ２Ｏ３ ,３ 例加用ＨＡ 或ＤＡ 方案。结果　２３ 例复发病人中１５例又获ＣＲ,１例ＰＲ,７ 例ＮＲ,这７ 例中３ 例应用Ａｓ２Ｏ３ ８ 周后改用ＨＡ或ＤＡ而达ＣＲ,４例１ 周内死亡。结论　初治的１３０ 例中７ 例ＮＲ可能存在内在性耐药,复发的２３ 例中也有７ 例表现为耐药性,可能是获得性耐药,而不是多药耐药,所以与ＡＴＲＡ等无交叉耐药,提示Ａｓ２Ｏ３ 的耐药不是单一机制可以解释的。     

Combination chemotherapy with cisplatin, ifosfamide and adriamycin in patients with advanced transitional cell carcinoma of the urinary tract

A combined chemotherapy with cisplatin, ifosfamide and adriamycin (CIA therapy) was performed in 20 patients with advanced transitional cell carcinoma of the urinary tract. Adriamycin 30mg/m2 and ifosfamide 1.5g/m2 were administered on day 1 and cisplatin 50 mg/m2 on day 2, which was repeated at intervals of 3 weeks, in principle. According to Koyama and Saito's response criteria, complete response (CR), partial response (PR) and minor response (MR) were obtained in 1, 4 and 5 cases, respectively; CR+PR+MR in 10 cases out of 18 evaluable cases (56%). The duration of response was 2 to 14 months (median; 4 months) in the cases with CR and PR. The survival time of the responders ranged from 3 to 23 months (median; 11 months), being significantly longer than that of the non-responders (p less than 0.05, Generalized Wilcoxon test). Adverse reactions observed were of a slight or moderate degree, with only a few cases of damage to renal function.